Education
About Us
Working with TipRanks
Follow Us
Else Nutrition Holdings Inc (TSE:BABY)
TSX:BABY
RESEARCH TOOLSreports
Top Page
Else Nutrition Holdings Inc
(TSX:BABY)
Rating:46Neutral
Price Target:―
Else Nutrition Holdings Inc (BABY) vs. iShares MSCI Canada ETF (EWC)
Market Cap
$6.81M
Dividend YieldN/A
Average Volume (3M)529.50K
Price to Earnings (P/E)―
Beta (1Y)0.77
Revenue Growth-5.13%
EPS Growth20.54%
CountryCA
Employees32
SectorConsumer Defensive
Sector Strength55
IndustryPackaged Foods
Share Statistics
EPS (TTM)N/A
Shares Outstanding340,368,320
10 Day Avg. Volume7,955
30 Day Avg. Volume529,495
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)7.30
Price to Sales (P/S)0.00
P/FCF Ratio-7.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Else Nutrition Holdings Inc Business Overview & Revenue Model
Company DescriptionElse Nutrition Holdings Inc (BABY) is a Canadian-based company operating in the food and beverage sector, specifically focusing on the development, production, and marketing of plant-based food products for infants, toddlers, children, and adults. The company is known for its innovative, clean-label, and dairy-free nutritional products, which serve as alternatives to traditional dairy-based formulas and snacks. Else Nutrition's flagship products include its plant-based toddler nutrition and complementary products aimed at addressing various dietary needs.
How the Company Makes MoneyElse Nutrition Holdings Inc makes money primarily through the sale of its plant-based nutritional products. The company's revenue model relies on direct-to-consumer sales via its online platform, as well as distribution through retail channels including health food stores, grocery stores, and pharmacies. Key revenue streams include its toddler nutrition product line and other plant-based offerings. Additionally, the company benefits from strategic partnerships and collaborations with retailers and distributors to expand its market reach and enhance brand awareness. Else Nutrition's focus on clean-label, allergen-friendly products helps it tap into the growing demand for plant-based diets and specialized nutrition.
Else Nutrition Holdings Inc Earnings Call Summary
Earnings Call Date:Jun 02, 2025
(Q3-2024)
| % Change Since: 11.11%|
Next Earnings Date:Jul 19, 2025
Earnings Call Sentiment Neutral
The earnings call presented a mixed outlook for Else Nutrition. While there are positive signs such as revenue growth, cost reduction efforts, and expansion in retail and online channels, the company faces challenges including sequential revenue decline, limited marketing budgets, negative gross profit, and delays in FDA approvals. The company is actively working on securing funding and partnerships to overcome these challenges.Q3-2024 Updates
Positive Updates
Revenue Growth
Revenue for the third quarter of 2024 was $1.8 million, representing a 5% growth from the prior year.
Cost Reduction Efforts
Implemented various cost-cutting measures leading to a 12% decrease in operational expenses amounting to CAD1.5 million year-to-date.
Retail Expansion
Pilot in Costco Canada stores could lead to distribution in over 100 locations. Advanced discussions for Ready-to-Drink Kids products in close to 900 U.S. stores.
Online Sales Channel Growth
Amazon.com remains the largest sales channel, with significant growth expected next year. Walmart.com is the second largest online channel, with additional contributions from an e-store, Thrive Market, and iHerb.
Negative Updates
Sequential Revenue Decline
Revenue declined sequentially due to timing delays in orders from key large retail partners.
Limited Marketing Budgets
Restricted marketing budgets limited the ability to support visibility and consumer demand generation.
Negative Gross Profit
Gross profit in Q3 2024 was minus CAD0.2 million, mainly due to a conservative inventory write-off.
FDA Approval Delays
Ongoing discussions with the FDA for infant formula approval, with no definitive timeframe for completion.
Company Guidance
During Else Nutrition's Third Quarter 2024 earnings call, CEO Hamutal Yitzhak outlined key financial and strategic metrics. The company reported a revenue of $1.8 million, marking a 5% year-over-year growth. However, this figure represented a decline from the previous quarter, due to delayed orders from major retail partners. Operating expenses remained stable at $3.6 million compared to the same period in 2023, while operational expenses saw a 12% year-to-date reduction, amounting to CAD1.5 million. The company's gross profit for Q3 2024 was negative CAD0.2 million, primarily due to an inventory write-off. To enhance financial health, Else Nutrition is working on securing non-dilutive long-term financing to replace existing convertible debt, aiming to boost marketing initiatives and achieve profitability by the end of 2026. The company also highlighted significant strides in retail expansion, including a Costco Canada pilot and potential placement of Ready-to-Drink Kids products in 900 U.S. stores. Online sales remain robust, with Amazon.com as the largest channel, followed by Walmart.com and other platforms.Else Nutrition Holdings Inc Financial Statement Overview
Summary
Else Nutrition Holdings Inc. is experiencing revenue growth, but struggles with profitability and cash flow management. Moderate leverage is evident, but a need for better equity and cash flow management is crucial for sustainability.Income Statement
Else Nutrition Holdings Inc. has seen revenue growth with a TTM revenue of $8.9 million, slightly down from $9.4 million in 2023. However, the company struggles with profitability, showing a negative gross profit margin and a net profit margin of -177.3% in the TTM period. This indicates high costs relative to revenue. The EBIT and EBITDA margins also reflect substantial operating losses.42
Neutral
Balance Sheet
The company's debt-to-equity ratio is 0.33, indicating moderate leverage. However, the equity ratio is weak at 49.5%, showing that liabilities form a significant portion of assets. Return on equity is severely negative due to continuous net losses. The balance sheet reflects a need for careful financial management to improve equity position.55
Neutral
Cash Flow
Else Nutrition's free cash flow is negative, showing a $12 million outflow in the TTM period. Operating cash flow is also negative, stressing liquidity. The operating cash flow to net income ratio indicates cash flow challenges. There is a need for better cash flow management to sustain operations without relying heavily on external financing.48
Neutral
| Breakdown | TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.91M | 9.36M | 8.53M | 4.69M | 1.48M | 554.00K |
| Gross Profit | -1.17M | -85.00K | 1.31M | 743.00K | 498.00K | 251.00K |
| EBITDA | -13.38M | -15.17M | -17.12M | -17.15M | -8.82M | -2.93M |
| Net Income | -15.80M | -15.61M | -17.61M | -1.62M | -24.10M | -5.38M |
Balance Sheet | ||||||
| Total Assets | 10.15M | 16.07M | 26.16M | 32.92M | 29.32M | 4.53M |
| Cash, Cash Equivalents and Short-Term Investments | 375.00K | 4.92M | 15.38M | 24.28M | 24.71M | 2.91M |
| Total Debt | 1.64M | 3.09M | 3.37M | 941.00K | 228.00K | 101.00K |
| Total Liabilities | 5.12M | 9.35M | 10.57M | 6.15M | 18.11M | 871.00K |
| Stockholders Equity | 5.02M | 6.72M | 15.60M | 26.77M | 11.21M | 3.66M |
Cash Flow | ||||||
| Free Cash Flow | -12.03M | -18.31M | -21.07M | -16.05M | -9.82M | -3.57M |
| Operating Cash Flow | -11.97M | -18.31M | -20.91M | -15.76M | -9.59M | -3.06M |
| Investing Cash Flow | 625.00K | -1.13M | 170.00K | 1.14M | -3.93M | -614.00K |
| Financing Cash Flow | 8.33M | 7.44M | 11.69M | 16.85M | 32.45M | 6.61M |
Else Nutrition Holdings Inc Technical Analysis
Positive
0.02
Price Trends
0.02
Positive
0.02
Positive
0.02
Negative
Market Momentum
<0.01
Negative
58.07
Neutral
<0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BABY, the sentiment is Positive. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.02, and below the 200-day MA of 0.02, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 58.07 is Neutral, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:BABY.
Else Nutrition Holdings Inc Peers Comparison
Overall Rating
UnderperformOutperform
Sector (53)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | C$21.89M | ― | -8.32% | ― | 63.93% | 61.35% | |
56 Neutral | C$24.64M | ― | -170.20% | ― | 0.38% | 7.22% | |
53 Neutral | C$4.43B | 3.67 | -22.83% | 4.45% | 8.13% | 2.00% | |
48 Neutral | C$54.40M | ― | -23.57% | ― | -7.65% | 31.15% | |
46 Neutral | $6.81M | ― | -351.09% | ― | -5.13% | 20.54% |
* Consumer Defensive Sector Average
Performance Comparison
TSE:BABY
Else Nutrition Holdings Inc
0.02
-0.17
-89.47%
TSE:TGO
TeraGo Inc.
1.36
-0.57
-29.53%
TSE:GURU
GURU Organic Energy Corp
1.77
-0.31
-14.90%
TSE:NEXE
NEXE Innovations
0.22
-0.06
-22.81%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.